11/14/2024 4:52 PM | Venrock Healthcare Capital Partners III, L.P. (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024 4:53 PM | Venrock Opportunities Fund, L.P. (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024 3:50 PM | PERCEPTIVE ADVISORS LLC (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
11/14/2024 3:33 PM | Paradigm Biocapital Advisors LP (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
11/12/2024 6:15 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/12/2024 6:15 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/18/2024 11:33 AM | STATE STREET CORP (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
|
09/30/2024 6:12 PM | Beetham Thomas W. (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/30/2024 6:10 PM | Mahoney Stephen F. (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/17/2024 8:00 PM | Fairmount Funds Management LLC (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13D/A | |
09/17/2024 8:00 PM | Fairmount Funds Management LLC (Reporting) Fairmount Healthcare Fund II GP LLC (Reporting) Fairmount Healthcare Fund II L.P. (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/13/2024 5:07 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 424B5 | |
09/12/2024 4:25 PM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
09/10/2024 3:28 PM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 424B5 | |
09/10/2024 6:11 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2024 7:25 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/08/2024 7:01 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
07/15/2024 5:31 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/28/2024 3:25 PM | Gheuens Sarah (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/20/2024 3:16 PM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/10/2024 7:05 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form DEFA14A | |
05/08/2024 6:51 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024 6:09 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/26/2024 7:30 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024 7:30 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024 7:32 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024 7:32 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024 7:34 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form ARS | |
04/26/2024 7:34 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form ARS | |
04/01/2024 5:38 PM | Fairmount Funds Management LLC (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13D/A | |
04/01/2024 5:32 PM | Fairmount Funds Management LLC (Reporting) Fairmount Healthcare Fund GP LLC (Reporting) Fairmount Healthcare Fund II GP LLC (Reporting) Fairmount Healthcare Fund II L.P. (Reporting) Fairmount Healthcare Fund L.P. (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/27/2024 3:34 PM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/14/2024 7:28 PM | Venrock Healthcare Capital Partners III, L.P. (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
02/14/2024 8:22 AM | BIOTECHNOLOGY VALUE FUND L P (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
01/29/2024 3:53 PM | PERCEPTIVE ADVISORS LLC (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G | |
01/29/2024 2:26 PM | BlackRock Inc. (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G/A | |
01/24/2024 5:44 PM | Fairmount Funds Management LLC (Reporting) Fairmount Healthcare Fund GP LLC (Reporting) Fairmount Healthcare Fund II GP LLC (Reporting) Fairmount Healthcare Fund II L.P. (Reporting) Fairmount Healthcare Fund L.P. (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/24/2024 7:13 AM | STATE STREET CORP (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G | |
01/19/2024 4:22 PM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/19/2024 3:32 PM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 424B5 | |
01/12/2024 3:31 PM | Ciulla Thomas (Reporting) Viridian Therapeutics, Inc.\DE (Issuer) Viridian Therapeutics (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
This company will win the AI race (Ad) Rome wasn’t built in a day…
But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence.
And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. |
01/10/2024 7:53 AM | FMR LLC (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G | |
01/08/2024 7:08 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/18/2023 10:45 AM | Meisner Lara (Reporting) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/18/2023 7:15 AM | Viridian Therapeutics, Inc.\DE (Filer) Viridian Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/12/2023 3:19 PM | Humer Kristian (Reporting) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/08/2023 3:17 PM | Venrock Opportunities Fund, L.P. (Filed by) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form SC 13G | |
12/07/2023 3:22 PM | Humer Kristian (Reporting) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
12/01/2023 3:04 PM | Meisner Lara (Reporting) Viridian Therapeutics, Inc.\DE (Subject) Viridian Therapeutics (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |